Evidence map›Paper›PMID 27959340›Full record

ArticleMolecular therapy. Nucleic acids2016

E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases.

Yoshihiro Morita, Mohamed Kamal, Shin-Ae Kang, Roy Zhang, Ganesh Lr Lokesh, Varatharasa Thiviyanathan, Nafis Hasan, Sukyung Woo, Daniel Zhao, Macall Leslie and 6 more

Open access · goldAbstract read
PubMed Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Recent Advances in Aptamer Discovery and Applications.Molecules (Basel, Switzerland) · 2019
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. miR-206/133b Cluster: A Weapon against Lung Cancer?Molecular therapy. Nucleic acids · 2017
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Yoshihiro MoritaUniversity of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Mohamed KamalUniversity of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Shin-Ae KangUniversity of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Roy ZhangDepartment of Pathology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Ganesh Lr LokeshInstitute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Varatharasa ThiviyanathanInstitute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Nafis HasanThomas Jefferson University, Philadelphia, Pennsylvania, USA.
Sukyung WooDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Daniel ZhaoUniversity of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City, Oklahoma, USA.
Macall LeslieUniversity of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Stephen SuhJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Wajeeha RazaqDepartment of Hematology and Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Hallgeir RuiDepartment of Pathology, Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, USA.
David G GorensteinAM Biotechnologies, Houston, Texas, USA.
David E VolkInstitute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Takemi TanakaUniversity of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
University of Oklahoma Health Sciences Center · USThe University of Texas Health Science Center at Houston · USHackensack University Medical Center · USMedical College of Wisconsin · USThomas Jefferson University · US

Funding

Texas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2010 to 2014
$12.4M
Prolactin pathways and metastatic progression of ER-positive breast cancerR01CA188575 · NCI · THOMAS JEFFERSON UNIVERSITY · PI RUI, HALLGEIR · 2015 to 2019
$1.8M
Anti-Migration Therapy for Prevention and Treatment of Breast TumorR01CA160271 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI TANAKA, TAKEMI · 2012 to 2016
$1.6M
NCI NIH HHS R01 CA160271NCI NIH HHS R01 CA188575NCI NIH HHS U54 CA151668
6 · The paper itself

Abstract

E-selectin is an adhesion molecule expressed on the luminal surface of inflamed blood vessels that mediates hematogenous metastasis by assisting shear-resistant adhesion of circulating tumor cells to the vessel surface under dynamic blood flow. Previously, we developed an E-selectin antagonistic thioaptamer (ESTA) for the prevention of hematogenous metastasis through the blockade of CD44

Identifiers

PMID27959340
OpenAlexW2561332231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.